Shopping Cart
Remove All
Your shopping cart is currently empty
NAT is a nicotinamide phosphoribosyltransferase (NAMPT) activator that increases intracellular NAD levels and induces subsequent metabolic and transcriptional reprogramming. It exhibits neuroprotective effects in a chemotherapy-induced peripheral neuropathy (CIPN) mouse model and may be employed in studies of neurodegenerative diseases or conditions associated with reduced NAD levels.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $34 | - | In Stock | |
| 5 mg | $72 | - | In Stock | |
| 10 mg | $98 | - | In Stock | |
| 25 mg | $168 | - | In Stock | |
| 50 mg | $247 | - | In Stock | |
| 100 mg | $365 | - | In Stock | |
| 200 mg | $542 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $89 | - | In Stock |
| Description | NAT is a nicotinamide phosphoribosyltransferase (NAMPT) activator that increases intracellular NAD levels and induces subsequent metabolic and transcriptional reprogramming. It exhibits neuroprotective effects in a chemotherapy-induced peripheral neuropathy (CIPN) mouse model and may be employed in studies of neurodegenerative diseases or conditions associated with reduced NAD levels. |
| Targets&IC50 | NAMPT:5.7 μM (EC50) |
| In vitro | NAT (10 µM) activates NAMPT (EC50=5.7 µM) and protects U2OS cells from the toxic effects of FK866. [1] |
| In vivo | In a chemotherapy-induced peripheral neuropathy (CIPN) mouse model, NAT (30 mg/kg, intraperitoneal injection, once daily for 2 weeks) exerted neuroprotective effects by elevating the mechanical hyperalgesia threshold. [1] |
| Synonyms | 2-(2-tert-butylphenoxy)-N-(4-hydroxyphenyl)acetamide |
| Molecular Weight | 299.36 |
| Formula | C18H21NO3 |
| Cas No. | 831243-31-3 |
| Smiles | O=C(NC1=CC=C(O)C=C1)COC=2C=CC=CC2C(C)(C)C |
| Color | White |
| Appearance | Solid |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO: ≥ 80 mg/mL, Sonication is recommended. |
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (11.02 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.